Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract- an update. Cancer Imaging 2014;14:14. [PMID: 25608662 PMCID: PMC4331820 DOI: 10.1186/1470-7330-14-14] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Accepted: 03/20/2014] [Indexed: 12/13/2022] Open

For:	Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract- an update. Cancer Imaging 2014;14:14. [PMID: 25608662 PMCID: PMC4331820 DOI: 10.1186/1470-7330-14-14] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Accepted: 03/20/2014] [Indexed: 12/13/2022] Open

Number

Cited by Other Article(s)

Li J, Yuan C, Pan Y, Yang Y, Lai N, Sheng X. Long-term survival after chemotherapy combined immunotherapy for recurrent mixed neuroendocrine-non-neuroendocrine neoplasms of the common bile duct. Clin J Gastroenterol 2025:10.1007/s12328-025-02128-9. [PMID: 40244371 DOI: 10.1007/s12328-025-02128-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2024] [Accepted: 04/01/2025] [Indexed: 04/18/2025]

Oishi R, Kobayashi S, Nagashima S, Fukushima T, Tezuka S, Morimoto M, Ueno M, Maeda S. Comparison of monotherapy and combination therapy for older patients with advanced biliary tract cancer: a retrospective study. BMC Cancer 2025;25:653. [PMID: 40205355 PMCID: PMC11984249 DOI: 10.1186/s12885-025-14014-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2024] [Accepted: 03/25/2025] [Indexed: 04/11/2025] Open

Abstract

BACKGROUND

The current standard first-line treatment for patients with advanced biliary tract cancer (BTC) is a combination chemotherapy regimen. However, whether the efficacy of combination therapy is superior to that of monotherapy in older patients with BTC remains unclear. Therefore, in this study, we aimed to compare the efficacy and safety of monotherapy with those of combination therapy in such patients.

METHODS

We retrospectively enrolled 157 patients with unresectable or recurrent BTC aged ≥ 75 years who received systemic chemotherapy between August 2011 and November 2020. We compared the efficacy and safety of combination therapy (gemcitabine [GEM] + cisplatin and GEM + S-1) with those of monotherapy (GEM or S-1 alone). We assessed patients' characteristics, survival, adverse events, and dose intensity. Statistical significance was set at p < 0.05.

RESULTS

Patients who received monotherapy were older and had worse performance status (PS), lower albumin levels, and higher carcinoembryonic antigen (CEA) levels than those who received combination therapy. The median overall survival (OS) was 16.4 and 12.8 months in the combination therapy and monotherapy groups, respectively (Hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.47-1.01), with a trend towards longer OS observed with combination therapy. However, multivariable analysis did not show superior OS with combination therapy (HR, 1.05; 95% CI, 0.66-1.68). Multivariable analysis also revealed gallbladder cancer, CEA, neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP) levels as prognostic factors for OS. Regarding safety, the incidence of grade ≥ 3 adverse events was significantly higher in the combination therapy group than in the monotherapy group (79% vs. 53%, p = 0.001); however, the rate of treatment discontinuation was approximately 10% in both groups, with no treatment-related deaths, suggesting that toxicities are manageable even in older patients.

CONCLUSIONS

Combination therapy is not necessarily recommended for older patients with BTC. Selecting an appropriate chemotherapy regimen based on an individual's condition is important.

Collapse

Albertini E, Miranda L, Maloberti T, de Biase D, Vasuri F. Morphologic and molecular diagnostic criteria of malignancies in biliary strictures. Histol Histopathol 2025;40:443-452. [PMID: 39381890 DOI: 10.14670/hh-18-811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/10/2024]

Qian H, Huang Y, Dong Y, Xu L, Chen R, Zhou F, Zhou D, Yu J, Lu B. A combined radiomics and clinical model for preoperative differentiation of intrahepatic cholangiocarcinoma and intrahepatic bile duct stones with cholangitis: a machine learning approach. Front Oncol 2025;15:1546940. [PMID: 40165897 PMCID: PMC11955465 DOI: 10.3389/fonc.2025.1546940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2024] [Accepted: 02/26/2025] [Indexed: 04/02/2025] Open

Abstract

Background

This study aimed to develop and validate a predictive model integrating radiomics features and clinical variables to differentiate intrahepatic bile duct stones with cholangitis (IBDS-IL) from intrahepatic cholangiocarcinoma (ICC) preoperatively, as accurate distinction is crucial for determining appropriate treatment strategies.

Methods

A total of 169 patients (97 IBDS-IL and 72 ICC) who underwent surgical resection were retrospectively analyzed. Radiomics features were extracted from ultrasound images, and clinical variables with significant differences between groups were identified. Feature selection was performed using LASSO regression and recursive feature elimination (RFE). The radiomics model, clinical model, and combined model were constructed and evaluated using the area under the curve (AUC), calibration curves, decision curve analysis (DCA), and SHAP analysis.

Results

The radiomics model achieved an AUC of 0.962, and the clinical model achieved an AUC of 0.861. The combined model, integrating the Radiomics Score with clinical variables, demonstrated the highest predictive performance with an AUC of 0.988, significantly outperforming the clinical model (p < 0.05). Calibration curves showed excellent agreement between predicted and observed outcomes, and the Hosmer-Lemeshow test confirmed a good model fit (p = 0.998). DCA revealed that the combined model provided the greatest clinical benefit across a wide range of threshold probabilities. SHAP analysis identified the Radiomics Score as the most significant contributor, complemented by abdominal pain and liver atrophy.

Conclusion

The combined model integrating radiomics features and clinical data offers a powerful and reliable tool for preoperative differentiation of IBDS-IL and ICC. Its superior performance and clinical interpretability highlight its potential for improving diagnostic accuracy and guiding clinical decision-making. Further validation in larger, multicenter datasets is warranted to confirm its generalizability.

Collapse

Alshwayyat S, Hanifa H, Alshwaiyat Y, Alshwayyat M, Alhussein H, Abu-Naja M, Alshwayyat TA, Alsaleh B, Shafa'a M, Alkurdi MF. Challenges in diagnosing and treating distal common bile duct adenocarcinoma: A case report with literature insights. Int J Emerg Med 2025;18:43. [PMID: 40033199 DOI: 10.1186/s12245-025-00859-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2024] [Accepted: 02/25/2025] [Indexed: 03/05/2025] Open

Zerunian M, Polidori T, Palmeri F, Nardacci S, Del Gaudio A, Masci B, Tremamunno G, Polici M, De Santis D, Pucciarelli F, Laghi A, Caruso D. Artificial Intelligence and Radiomics in Cholangiocarcinoma: A Comprehensive Review. Diagnostics (Basel) 2025;15:148. [PMID: 39857033 PMCID: PMC11763775 DOI: 10.3390/diagnostics15020148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2024] [Revised: 01/01/2025] [Accepted: 01/07/2025] [Indexed: 01/27/2025] Open

Affiliation(s)

Marta Zerunian Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)
Tiziano Polidori Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)
Federica Palmeri Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)
Stefano Nardacci Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)
Antonella Del Gaudio Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)
Benedetta Masci Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)
Giuseppe Tremamunno Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)
Michela Polici Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.) PhD School in Translational Medicine and Oncology, Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy
Domenico De Santis Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)
Francesco Pucciarelli Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)
Andrea Laghi Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)
Damiano Caruso Department of Medical Surgical Sciences and Translational Medicine, Sapienza–University of Rome, Radiology Unit–Sant’Andrea University Hospital, 00189 Rome, Italy; (T.P.); (F.P.); (S.N.); (A.D.G.); (B.M.); (G.T.); (M.P.); (D.D.S.); (F.P.); (A.L.); (D.C.)

Collapse

Yong YSS, Lee ZR, Soh YTN, Low SCA. Preoperative Imaging Assessment and Staging of Perihilar Cholangiocarcinoma: Tips and Pitfalls. JOURNAL OF THE KOREAN SOCIETY OF RADIOLOGY 2025;86:45-67. [PMID: 39958497 PMCID: PMC11822288 DOI: 10.3348/jksr.2024.0055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/15/2024] [Revised: 07/30/2024] [Accepted: 10/01/2024] [Indexed: 02/18/2025]

Murakami T, Shimizu H, Nojima H, Shuto K, Usui A, Kosugi C, Koda K. Diffusion-Weighted Magnetic Resonance Imaging for the Diagnosis of Lymph Node Metastasis in Patients with Biliary Tract Cancer. Cancers (Basel) 2024;16:3143. [PMID: 39335116 PMCID: PMC11430223 DOI: 10.3390/cancers16183143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2024] [Revised: 09/03/2024] [Accepted: 09/07/2024] [Indexed: 09/30/2024] Open

Özdemir M, Koç U, Gökhan MB, Beşler MS. Unveiling the potential of strain elastography in perihilar cholangiocarcinoma biopsies. Abdom Radiol (NY) 2024;49:3143-3148. [PMID: 38557769 DOI: 10.1007/s00261-024-04255-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 02/13/2024] [Accepted: 02/14/2024] [Indexed: 04/04/2024]

Zhu D, Abuduhelili A, Tulahong A, Liu C, Jiang T, Shao Y, Aji T. A special case of intrahepatic cholangiocarcinoma misdiagnosed as hepatic cystic echinococcosis. Heliyon 2024;10:e35073. [PMID: 39161843 PMCID: PMC11332812 DOI: 10.1016/j.heliyon.2024.e35073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2024] [Revised: 07/10/2024] [Accepted: 07/22/2024] [Indexed: 08/21/2024] Open

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a prevalent liver tumor that presents a diagnostic challenge due to its nonspecific symptoms, necessitating reliance on imaging techniques for accurate diagnosis. The similarity of imaging features with other liver diseases, such as hepatocellular carcinoma (HCC) and hepatic alveolar echinococcosis, often leads to confusion and misdiagnosis. In contrast, the distinct characteristics of hepatic cystic echinococcosis (HCE) result in fewer reported misdiagnoses. A case involving a 53-year-old female from Changji (Xinjiang, China) diagnosed with iCCA, who was hospitalized for symptoms of upper abdominal distension and pain, along with nausea and vomiting, is presented. The patient underwent a partial hepatectomy in 1990 for hepatic echinococcosis. Abdominal computed tomography revealed multiple, quasicircular, low-density masses in the hilar region and right anterior lobe of the liver, with the largest measuring 5.61 cm × 4.84 cm. Enhanced computed tomography did not reveal significant enhancement of the lesion. Considering epidemiological factors, medical history, and imaging findings, the initial diagnosis was HCE, which prompted surgical intervention. The diagnosis of iCCA with necrosis was confirmed via pathological examination. The literature and relevant sources were consulted to establish that biliary tract tumors with necrosis or mucin production typically do not exhibit significant enhancement in enhanced scans, maintaining a consistently low density across all phases, resembling the presentation of HCE. When making diagnoses based on imaging data, it is essential to have knowledge of both the typical features and unique manifestations of the disease. In specific instances, relying solely on epidemiology and medical history may lead to incorrect conclusions. Therefore, comprehensive consideration of all aspects is necessary to prevent missed diagnoses and misdiagnoses.

Collapse

Affiliation(s)

Dalong Zhu Department of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China Xinjiang Uyghur Autonomous Region Clinical Research Center for Echinococcosis and Hepatobiliary Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China
Abuduhaiwaier Abuduhelili Department of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China Xinjiang Uyghur Autonomous Region Clinical Research Center for Echinococcosis and Hepatobiliary Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China
Alimu Tulahong Department of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China Xinjiang Uyghur Autonomous Region Clinical Research Center for Echinococcosis and Hepatobiliary Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China
Chang Liu The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China
Tiemin Jiang Department of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China Xinjiang Uyghur Autonomous Region Clinical Research Center for Echinococcosis and Hepatobiliary Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China
Yingmei Shao Department of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China Xinjiang Uyghur Autonomous Region Clinical Research Center for Echinococcosis and Hepatobiliary Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China
Tuerganaili Aji Department of Hepatobiliary and Echinococcosis Surgery, Digestive and Vascular Surgery Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China Xinjiang Uyghur Autonomous Region Clinical Research Center for Echinococcosis and Hepatobiliary Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, Xinjiang Uygur Autonomous Region, China

Collapse

Gupta P, Basu S, Arora C. Applications of artificial intelligence in biliary tract cancers. Indian J Gastroenterol 2024;43:717-728. [PMID: 38427281 DOI: 10.1007/s12664-024-01518-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Accepted: 12/29/2023] [Indexed: 03/02/2024]

Sehrawat A, Gopi VP, Gupta A. A Systematic Review on Role of Deep Learning in CT scan for Detection of Gall Bladder Cancer. ARCHIVES OF COMPUTATIONAL METHODS IN ENGINEERING 2024;31:3303-3311. [DOI: 10.1007/s11831-024-10073-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Accepted: 01/17/2024] [Indexed: 04/01/2025]

Cao J, Srinivas-Rao S, Mroueh N, Anand R, Kongboonvijit S, Sertic M, Shenoy-Bhangle AS, Kambadakone A. Cholangiocarcinoma imaging: from diagnosis to response assessment. Abdom Radiol (NY) 2024;49:1699-1715. [PMID: 38578323 DOI: 10.1007/s00261-024-04267-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 02/21/2024] [Accepted: 02/22/2024] [Indexed: 04/06/2024]

Liu N, Wu Y, Tao Y, Zheng J, Huang X, Yang L, Zhang X. Differentiation of Hepatocellular Carcinoma from Intrahepatic Cholangiocarcinoma through MRI Radiomics. Cancers (Basel) 2023;15:5373. [PMID: 38001633 PMCID: PMC10670473 DOI: 10.3390/cancers15225373] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 10/25/2023] [Accepted: 11/06/2023] [Indexed: 11/26/2023] Open

Abstract

The purpose of this study was to investigate the efficacy of magnetic resonance imaging (MRI) radiomics in differentiating hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (ICC). The clinical and MRI data of 129 pathologically confirmed HCC patients and 48 ICC patients treated at the Affiliated Hospital of North Sichuan Medical College between April 2016 and December 2021 were retrospectively analyzed. The patients were randomly divided at a ratio of 7:3 into a training group of 124 patients (90 with HCC and 34 with ICC) and a validation group of 53 patients (39 with HCC and 14 with ICC). Radiomic features were extracted from axial fat suppression T2-weighted imaging (FS-T2WI) and axial arterial-phase (AP) and portal-venous-phase (PVP) dynamic-contrast-enhanced MRI (DCE-MRI) sequences, and the corresponding datasets were generated. The least absolute shrinkage and selection operator (LASSO) method was used to select the best radiomic features. Logistic regression was used to establish radiomic models for each sequence (FS-T2WI, AP and PVP models), a clinical model for optimal clinical variables (C model) and a joint radiomics model (JR model) integrating the radiomics features of all the sequences as well as a radiomics-clinical model combining optimal radiomic features and clinical risk factors (RC model). The performance of each model was evaluated using the area under the receiver operating characteristic curve (AUC). The AUCs of the FS-T2WI, AP, PVP, JR, C and RC models for distinguishing HCC from ICC were 0.693, 0.863, 0.818, 0.914, 0.936 and 0.977 in the training group and 0.690, 0.784, 0.727, 0.802, 0.860 and 0.877 in the validation group, respectively. The results of this study suggest that MRI-based radiomics may help noninvasively differentiate HCC from ICC. The model integrating the radiomics features and clinical risk factors showed a further improvement in performance.

Collapse

Affiliation(s)

Ning Liu Medical Imaging Key Laboratory of Sichuan Province, Interventional Medical Center, Department of Radiology, Medical Research Center, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China; (N.L.); (Y.W.); (Y.T.); (J.Z.); (X.H.); (X.Z.) Hospital of Chengdu Office of People’s Government of Tibetan Autonomous Region (Hospital. C.T.), Chengdu 610041, China
Yaokun Wu Medical Imaging Key Laboratory of Sichuan Province, Interventional Medical Center, Department of Radiology, Medical Research Center, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China; (N.L.); (Y.W.); (Y.T.); (J.Z.); (X.H.); (X.Z.)
Yunyun Tao Medical Imaging Key Laboratory of Sichuan Province, Interventional Medical Center, Department of Radiology, Medical Research Center, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China; (N.L.); (Y.W.); (Y.T.); (J.Z.); (X.H.); (X.Z.)
Jing Zheng Medical Imaging Key Laboratory of Sichuan Province, Interventional Medical Center, Department of Radiology, Medical Research Center, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China; (N.L.); (Y.W.); (Y.T.); (J.Z.); (X.H.); (X.Z.)
Xiaohua Huang Medical Imaging Key Laboratory of Sichuan Province, Interventional Medical Center, Department of Radiology, Medical Research Center, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China; (N.L.); (Y.W.); (Y.T.); (J.Z.); (X.H.); (X.Z.)
Lin Yang Medical Imaging Key Laboratory of Sichuan Province, Interventional Medical Center, Department of Radiology, Medical Research Center, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China; (N.L.); (Y.W.); (Y.T.); (J.Z.); (X.H.); (X.Z.)
Xiaoming Zhang Medical Imaging Key Laboratory of Sichuan Province, Interventional Medical Center, Department of Radiology, Medical Research Center, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China; (N.L.); (Y.W.); (Y.T.); (J.Z.); (X.H.); (X.Z.)

Collapse

Wen W, Mumma M, Zheng W. Temporal Trends of Stages and Survival of Biliary Tract Cancers in the United States and Associations with Demographic Factors. Cancer Epidemiol Biomarkers Prev 2023;32:1660-1667. [PMID: 37606709 PMCID: PMC10840886 DOI: 10.1158/1055-9965.epi-23-0562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 07/26/2023] [Accepted: 08/16/2023] [Indexed: 08/23/2023] Open

Pang L, Mao W, Zhang Y, Liu G, Hu P, Chen S, Gu Y, Wang Y, Liu H, Shi H. Comparison of ¹⁸F-FDG PET/MR and PET/CT for pretreatment TNM staging of hilar cholangiocarcinoma. Abdom Radiol (NY) 2023;48:2537-2546. [PMID: 37179282 DOI: 10.1007/s00261-023-03925-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 04/18/2023] [Accepted: 04/18/2023] [Indexed: 05/15/2023]

Affiliation(s)

Lifang Pang Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China Shanghai Institute of Medical Imaging, Shanghai, 200032, China Institute of Nuclear Medicine, Fudan University, Shanghai, 200032, China Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
Wujian Mao Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China Shanghai Institute of Medical Imaging, Shanghai, 200032, China Institute of Nuclear Medicine, Fudan University, Shanghai, 200032, China Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
Yiqiu Zhang Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China Shanghai Institute of Medical Imaging, Shanghai, 200032, China Institute of Nuclear Medicine, Fudan University, Shanghai, 200032, China Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
Guobing Liu Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China Shanghai Institute of Medical Imaging, Shanghai, 200032, China Institute of Nuclear Medicine, Fudan University, Shanghai, 200032, China Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
Pengcheng Hu Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China Shanghai Institute of Medical Imaging, Shanghai, 200032, China Institute of Nuclear Medicine, Fudan University, Shanghai, 200032, China Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
Shuguang Chen Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China Shanghai Institute of Medical Imaging, Shanghai, 200032, China Institute of Nuclear Medicine, Fudan University, Shanghai, 200032, China
Yushen Gu Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China Shanghai Institute of Medical Imaging, Shanghai, 200032, China Institute of Nuclear Medicine, Fudan University, Shanghai, 200032, China
Yueqi Wang Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China Department of General Surgery, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China Biliary Tract Diseases Institute, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China
Houbao Liu Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Department of General Surgery, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China. Biliary Tract Diseases Institute, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, China. General Surgery Department, Zhongshan-Xuhui Hospital Affiliated to Fudan University, No. 966, Middle Huaihai Rd, Shanghai, 200031, China.
Hongcheng Shi Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China. Shanghai Institute of Medical Imaging, Shanghai, 200032, China. Institute of Nuclear Medicine, Fudan University, Shanghai, 200032, China. Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Collapse

Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. Dig Dis Sci 2022;67:4633-4653. [PMID: 35908126 DOI: 10.1007/s10620-022-07616-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/27/2022] [Indexed: 12/14/2022]

Vij M, Puri Y, Rammohan A, G G, Rajalingam R, Kaliamoorthy I, Rela M. Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review. World J Gastrointest Oncol 2022;14:607-627. [PMID: 35321284 PMCID: PMC8919011 DOI: 10.4251/wjgo.v14.i3.607] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2021] [Revised: 12/13/2021] [Accepted: 02/23/2022] [Indexed: 02/06/2023] Open

Manne A, Woods E, Tsung A, Mittra A. Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology. Front Oncol 2021;11:768009. [PMID: 34868996 PMCID: PMC8634105 DOI: 10.3389/fonc.2021.768009] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 10/13/2021] [Indexed: 12/12/2022] Open

Abstract

The effective management of biliary tract cancers (BTCs) has been hampered by limited options for systemic therapy. In recent years, the focus on precision medicine has made technologies such as next-generation sequencing (NGS) accessible to clinicians to identify targetable mutations in BTCs in tumor tissue (primarily) as well as blood, and to treat them with targeted therapies when possible. It has also expanded our understanding of functional pathways associated with genetic alterations and opened doors for identifying novel targets for treatment. Recent advances in the precision medicine approach allowed us to identify new molecular markers in BTCs, such as epigenetic changes (methylation and histone modification) and non-DNA markers such as messenger RNA, microRNA, and long non-coding RNA. It also made detecting these markers from non-traditional sources such as blood, urine, bile, and cytology (from fine-needle aspiration and biliary brushings) possible. As these tests become more accessible, we can see the integration of different molecular markers from all available sources to aid physicians in diagnosing, assessing prognosis, predicting tumor response, and screening BTCs. Currently, there are a handful of approved targeted therapies and only one class of immunotherapy agents (immune checkpoint inhibitors or ICIs) to treat BTCs. Early success with new targets, vascular endothelial growth factor receptor (VEGFR), HER2, protein kinase receptor, and Dickkopf-1 (DKK1); new drugs for known targets, fibroblast growth factor receptors (FGFRs) such as futabatinib, derazantinib, and erdafitinib; and ICIs such as durvalumab and tremelimumab is encouraging. Novel immunotherapy agents such as bispecific antibodies (bintrafusp alfa), arginase inhibitors, vaccines, and cellular therapy (chimeric antigen receptor-T cell or CAR-T, natural killer cells, tumor-infiltrating lymphocytes) have the potential to improve outcomes of BTCs in the coming years.

Collapse

Detection of Human Cholangiocarcinoma Markers in Serum Using Infrared Spectroscopy. Cancers (Basel) 2021;13:cancers13205109. [PMID: 34680259 PMCID: PMC8534168 DOI: 10.3390/cancers13205109] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 10/07/2021] [Accepted: 10/08/2021] [Indexed: 12/21/2022] Open

Abstract

Simple Summary

Cholangiocarcinoma is a form of liver cancer that is found, predominantly, in Thailand. Due to the non-specific symptoms and laboratory investigation, it is difficult to rule out cholangiocarcinoma from other liver conditions. Here, we demonstrate the development of a diagnostic tool for cholangiocarcinoma, based on the ATR-FTIR analyses of sera, coupled with multivariate analyses and machine learning tools to obtain a better specificity. The innovative approach that shows highly promising results for this otherwise difficult to diagnose cancer.

Abstract

Cholangiocarcinoma (CCA) is a malignancy of the bile duct epithelium. Opisthorchis viverrini infection is a known high-risk factor for CCA and in found, predominantly, in Northeast Thailand. The silent disease development and ineffective diagnosis have led to late-stage detection and reduction in the survival rate. Attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) is currently being explored as a diagnostic tool in medicine. In this study, we apply ATR-FTIR to discriminate CCA sera from hepatocellular carcinoma (HCC), biliary disease (BD) and healthy donors using a multivariate analysis. Spectral markers differing from healthy ones are observed in the collagen band at 1284, 1339 and 1035 cm⁻¹, the phosphate band (vsPO2−) at 1073 cm⁻¹, the polysaccharides band at 1152 cm⁻¹ and 1747 cm⁻¹ of lipid ester carbonyl. A Principal Component Analysis (PCA) shows discrimination between CCA and healthy sera using the 1400–1000 cm⁻¹ region and the combined 1800—1700 + 1400–1000 cm⁻¹ region. Partial Least Square-Discriminant Analysis (PLS-DA) scores plots in four of five regions investigated, namely, the 1400–1000 cm⁻¹, 1800–1000 cm⁻¹, 3000–2800 + 1800–1000 cm⁻¹ and 1800–1700 + 1400–1000 cm⁻¹ regions, show discrimination between sera from CCA and healthy volunteers. It was not possible to separate CCA from HCC and BD by PCA and PLS-DA. CCA spectral modelling is established using the PLS-DA, Support Vector Machine (SVM), Random Forest (RF) and Neural Network (NN). The best model is the NN, which achieved a sensitivity of 80–100% and a specificity between 83 and 100% for CCA, depending on the spectral window used to model the spectra. This study demonstrates the potential of ATR-FTIR spectroscopy and spectral modelling as an additional tool to discriminate CCA from other conditions.

Collapse

Yoo J, Kim JH, Bae JS, Kang HJ. Prediction of prognosis and resectability using MR imaging, clinical, and histopathological findings in patients with perihilar cholangiocarcinoma. Abdom Radiol (NY) 2021;46:4159-4169. [PMID: 33929600 DOI: 10.1007/s00261-021-03101-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 04/13/2021] [Accepted: 04/21/2021] [Indexed: 02/08/2023]

Abstract

PURPOSE

To predict poor overall survival (OS) and risk of residual tumor after surgery using MR imaging, clinical, and histopathological findings in perihilar cholangiocarcinoma.

METHODS

196 patients with perihilar cholangiocarcinoma who underwent preoperative MRI and curative-intent surgery were retrospectively included. MRI findings were assessed by two radiologists. Clinical characteristics and histopathological results such as serum carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), T and N stage, and resection status, were also investigated. Cox regression analysis and the Kaplan-Meier method were used to identify prognostic factors for OS. We further analyzed the correlation between MRI features and residual tumors using logistic regression analysis.

RESULTS

The median OS was 25.0 ± 26.6 months. T stage (hazard ratio [HR] 6.26, p = 0.014), N stage (HR 1.86, p = 0.002), CA-19-9 >37 U/mL (HR 2.06, p < 0.001), enlarged LN on MRI (HR 1.69, p = 0.006), and residual tumor (HR 1.52, p = 0.034) were important predictors of poor survival. The 5-year OS of the complete resection group (n = 107) was significantly better than that of the residual tumor group (n = 89) (35.5% vs. 18.8%, p = 0.002). Additionally, peritumoral fat stranding (odds ratio[OR] 2.09, p = 0.027), Bismuth type III/IV (OR 1.95, p = 0.022), and common bile duct (CBD) involvement (OR 2.3, p = 0.008) on MRI were important predictors of residual tumors in univariate analyses. However, absence of peritumoral fat stranding was a significant independent predictor for complete resection (OR 1.99, p = 0.048) and showed the highest sensitivity, at 79.8%.

CONCLUSION

MR imaging, clinical and histopathological results are useful for predicting poor survival after surgery for perihilar cholangiocarcinoma. Furthermore, MRI findings, including peritumoral fat stranding, CBD involvement, and Bismuth type, are important for the prediction of residual tumors.

Collapse

Sarcognato S, Sacchi D, Fassan M, Fabris L, Cadamuro M, Zanus G, Cataldo I, Capelli P, Baciorri F, Cacciatore M, Guido M. Cholangiocarcinoma. Pathologica 2021;113:158-169. [PMID: 34294934 PMCID: PMC8299326 DOI: 10.32074/1591-951x-252] [Citation(s) in RCA: 99] [Impact Index Per Article: 24.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Accepted: 01/04/2021] [Indexed: 12/27/2022] Open

Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 PMCID: PMC8198554 DOI: 10.3390/cancers13112708] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2021] [Revised: 05/25/2021] [Accepted: 05/27/2021] [Indexed: 12/24/2022] Open

Ichikawa S, Oishi N, Kondo T, Onishi H. Key Imaging Findings for the Prospective Diagnosis of Rare Diseases of the Gallbladder and Cystic Duct. Korean J Radiol 2021;22:1462-1474. [PMID: 34132078 PMCID: PMC8390821 DOI: 10.3348/kjr.2020.1479] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 03/09/2021] [Accepted: 03/17/2021] [Indexed: 11/15/2022] Open

Han Y, Zhang H, Zhou Z, Liu R, Liu D, Bai M, Fan Q, Li J, Zhu K, Li H, Ning T, Ying G, Ba Y. Serum microRNAs as Biomarkers for the Noninvasive Early Diagnosis of Biliary Tract Cancer. Int J Gen Med 2021;14:1185-1195. [PMID: 33833559 PMCID: PMC8021261 DOI: 10.2147/ijgm.s297371] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Accepted: 03/15/2021] [Indexed: 12/16/2022] Open

Affiliation(s)

Yueting Han Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Haiyang Zhang Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Zhengyang Zhou Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Rui Liu Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Dongying Liu Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Ming Bai Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Qian Fan Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Jialu Li Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Jiao-Tong University School of Medicine Renji Hospital, Shanghai, 200001, People's Republic of China
Kegan Zhu Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Hongli Li Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Tao Ning Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Guoguang Ying Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China
Yi Ba Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China

Collapse

Solonitsyn E, Dechêne A. Diagnostic Approach to Suspected Perihilar Malignancy. Visc Med 2021;37:3-9. [PMID: 33718479 DOI: 10.1159/000513950] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Accepted: 12/18/2020] [Indexed: 12/14/2022] Open

Chatchawal P, Wongwattanakul M, Tippayawat P, Jearanaikoon N, Jumniansong A, Boonmars T, Jearanaikoon P, Wood BR. Monitoring the Progression of Liver Fluke-Induced Cholangiocarcinoma in a Hamster Model Using Synchrotron FTIR Microspectroscopy and Focal Plane Array Infrared Imaging. Anal Chem 2020;92:15361-15369. [PMID: 33170647 DOI: 10.1021/acs.analchem.0c02656] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]

Abstract

Cholangiocarcinoma (CCA) is a bile duct cancer that originates in the bile duct epithelium. Northeastern Thailand has the highest incidence of CCA, and there is a direct correlation with liver fluke (Opisthorchis viverrini) infection. The high mortality rate of CCA is a consequence of delayed diagnosis. Fourier transform infrared (FTIR) spectroscopy is a powerful technique that detects the absorbance of molecular vibrations and is perfectly suited for the interrogation of biological samples. In this study, we applied synchrotron radiation-FTIR (SR-FTIR) microspectroscopy and focal plane array (FPA-FTIR) microspectroscopy to characterize periductal fibrosis and bile duct cells progressing to CCA induced by inoculating O. viverrini metacercariae into hamsters. SR-FTIR and FPA-FTIR measurements were performed in liver sections harvested from 1-, 2-, 3-, and 6-month post-infected hamsters compared to uninfected liver tissues. Principal component analysis (PCA) of the tissue samples showed a clear discrimination among uninfected and early-stage (1 and 2 months) and cancerous-stage (3 and 6 months) tissues. The discrimination is based on intensity changes in the phosphodiester band (1081 cm^-1), amino acid residue (∼1396 cm^-1), and C═O stretching carboxylic esters (1745 cm^-1). Infected tissues also show definitive bands at ∼1280, 1234, and 1201 cm^-1 characteristic of the collagen triplet and indicative of fibrosis. Hierarchical cluster analysis (HCA) was performed on the FPA data and showed a classification into specific cell types. Hepatocyte, fibrotic lesion, and bile duct (cancer) were classified and HCA mapping showed similar cellular distribution pattern compared to Sirius red staining. This study was also extended to less invasive sample analysis using attenuated total reflectance-FTIR (ATR-FTIR) spectroscopy. Sera from O. viverrini-infected and uninfected hamsters were analyzed using multivariate analysis, including principal component analysis (PCA), and partial least squares-discriminant analysis (PLS-DA). PCA was able to classify spectra of normal, early-stage CCA, and CCA, while the PLS-DA gave 100% accuracy for the validation. The model was established from 17 samples (11 normal, 6 cancer) in the calibration set and 9 samples in the validation set (4 normal, 2 cancer, 3 precancerous). These results indicate that FTIR-based technology is a potential tool to detect the progression of CCA, especially in the early stages of the disease.

Collapse

Huang D, Lee J, Song N, Cho S, Choe S, Shin A. Gallstones, Cholecystectomy and the Risk of Hepatobiliary and Pancreatic Cancer: A Nationwide Population-based Cohort Study in Korea. J Cancer Prev 2020;25:164-172. [PMID: 33033710 PMCID: PMC7523037 DOI: 10.15430/jcp.2020.25.3.164] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Revised: 09/21/2020] [Accepted: 09/21/2020] [Indexed: 11/03/2022] Open

Inchingolo R, Maino C, Gatti M, Tricarico E, Nardella M, Grazioli L, Sironi S, Ippolito D, Faletti R. Gadoxetic acid magnetic-enhanced resonance imaging in the diagnosis of cholangiocarcinoma. World J Gastroenterol 2020;26:4261-4271. [PMID: 32848332 PMCID: PMC7422539 DOI: 10.3748/wjg.v26.i29.4261] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Revised: 06/16/2020] [Accepted: 07/22/2020] [Indexed: 02/06/2023] Open

de Savornin Lohman E, de Bitter T, Verhoeven R, van der Geest L, Hagendoorn J, Haj Mohammad N, Daams F, Klümpen HJ, van Gulik T, Erdmann J, de Boer M, Hoogwater F, Koerkamp BG, Braat A, Verheij J, Nagtegaal I, van Laarhoven C, van den Boezem P, van der Post R, de Reuver P. Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort. Cancers (Basel) 2020;12:cancers12040918. [PMID: 32283627 PMCID: PMC7226578 DOI: 10.3390/cancers12040918] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 03/31/2020] [Accepted: 04/03/2020] [Indexed: 12/29/2022] Open

Affiliation(s)

Elise de Savornin Lohman Department of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands; (E.d.S.L.); (R.V.); (C.v.L.); (P.v.d.B.)
Tessa de Bitter Department of Pathology, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands; (T.d.B.); (I.N.); (R.v.d.P.)
Rob Verhoeven Department of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands; (E.d.S.L.); (R.V.); (C.v.L.); (P.v.d.B.) Department of Research, Netherlands Comprehensive Cancer Organization, 3501 DB Utrecht, The Netherlands;
Lydia van der Geest Department of Research, Netherlands Comprehensive Cancer Organization, 3501 DB Utrecht, The Netherlands;
Jeroen Hagendoorn Department of Surgery, Utrecht University Medical Center, 3508 GA Utrecht, The Netherlands;
Nadia Haj Mohammad Department of Medical Oncology, Utrecht University Medical Center, Utrecht University, 3508 GA Utrecht, The Netherlands;
Freek Daams Department of Surgery, Amsterdam University Medical Centers, VU University, Cancer Center Amsterdam, 1007 MB Amsterdam, The Netherlands;
Heinz-Josef Klümpen Department of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, 1100 DD Amsterdam, The Netherlands;
Thomas van Gulik Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, 1100DD Amsterdam, The Netherlands; (T.v.G.); (J.E.)
Joris Erdmann Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, 1100DD Amsterdam, The Netherlands; (T.v.G.); (J.E.)
Marieke de Boer Department of Surgery, Section of HPB-Surgery and Liver Transplantation, University Medical Center Groningen, 97700 RB Groningen, The Netherlands; (M.d.B.); (F.H.)
Frederik Hoogwater Department of Surgery, Section of HPB-Surgery and Liver Transplantation, University Medical Center Groningen, 97700 RB Groningen, The Netherlands; (M.d.B.); (F.H.)
Bas Groot Koerkamp Department of Surgery, Erasmus MC, 3000 CB Rotterdam, The Netherlands;
Andries Braat Department of Surgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands;
Joanne Verheij Department of Pathology, Amsterdam University Medical Center, 1100 DD Amsterdam, The Netherlands;
Iris Nagtegaal Department of Pathology, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands; (T.d.B.); (I.N.); (R.v.d.P.)
Cornelis van Laarhoven Department of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands; (E.d.S.L.); (R.V.); (C.v.L.); (P.v.d.B.)
Peter van den Boezem Department of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands; (E.d.S.L.); (R.V.); (C.v.L.); (P.v.d.B.)
Rachel van der Post Department of Pathology, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands; (T.d.B.); (I.N.); (R.v.d.P.)
Philip de Reuver Department of Surgery, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands; (E.d.S.L.); (R.V.); (C.v.L.); (P.v.d.B.) Correspondence: ; Tel./Fax: +31-24-3613983

Collapse

Khuntikeo N, Titapun A, Chamadol N, Boonphongsathien W, Sa-Ngiamwibool P, Taylor-Robinson SD, Wadsworth CA, Zhang S, Kardoulaki EM, Young IR, Syms RRA. Improving the Detection of Cholangiocarcinoma: In vitro MRI-Based Study Using Local Coils and T2 Mapping. Hepat Med 2020;12:29-39. [PMID: 32280284 PMCID: PMC7127873 DOI: 10.2147/hmer.s232392] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 02/20/2020] [Indexed: 12/15/2022] Open

Satiya J, Mousa OY, Gupta K, Trivedi S, Oman SP, Wijarnpreecha K, Harnois DM, Corral JE. Diagnostic yield of magnetic resonance imaging for cholangiocarcinoma in primary sclerosing cholangitis: a meta-analysis. Clin Exp Hepatol 2020;6:35-41. [PMID: 32166122 PMCID: PMC7062114 DOI: 10.5114/ceh.2020.93054] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 11/07/2019] [Indexed: 02/07/2023] Open

Abstract

AIM OF THE STUDY

Combined magnetic resonance imaging and magnetic resonance cholangiopancreatography (MRI/MRCP) can identify biliary strictures and diagnose primary sclerosing cholangitis (PSC). Diagnosis of cholangiocarcinoma in patients with PSC remains challenging, and the accuracy of MRI/MRCP has not been completely established. We aimed to determine the sensitivity and specificity of MRI/MRCP in the diagnosis of cholangiocarcinoma among patients with PSC from the published literature.

MATERIAL AND METHODS

We searched Embase, PubMed, Cochrane, Scopus, ClinicalTrials.gov, and abstracts from relevant scientific meetings and performed a systematic review and meta-analysis to estimate the diagnostic yield of MRI/MRCP in patients with PSC. Sensitivity and specificity were calculated from pooled estimates of cholangiocarcinoma cases identified and lesions missed. Modifying variables were included in a meta-regression model.

RESULTS

Our literature search yielded 302 articles and 9 conference abstracts; 8 studies involving 846 liver patients from 5 countries were included in the final analysis. Of those, 531 had PSC and received MRI/MRCP. Thirty-six (6.8%) patients were diagnosed with cholangiocarcinoma (33 true positive, 3 false negative and 1 false positive). Pooled sensitivity was 98.9% (95% CI: 98.6-99.3%). Cholangiocarcinoma cases missed by MRI/MRCP were diagnosed as beading irregularities of the central hepatic ducts, or PSC-related diffuse stricture. Metaregression revealed that neither publication year, study design, nor sample size had a significant effect on observed cancer rates (p = 0.9, 0.3, and 0.3, respectively).

CONCLUSIONS

MRI/MRCP followed by endoscopic retrograde cholangiopancreatography (ERCP) is a sensitive and specific tool to diagnose cholangiocarcinoma among patients with PSC. Further research should estimate MRI/MRCP diagnostic accuracy for cholangiocarcinoma using prospective methodology and longer term outcomes.

Collapse

Rapidly growing neuroendocrine carcinoma of the gallbladder: A case report. Radiol Case Rep 2020;15:259-265. [PMID: 31956384 PMCID: PMC6957802 DOI: 10.1016/j.radcr.2019.12.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Revised: 12/08/2019] [Accepted: 12/16/2019] [Indexed: 12/16/2022] Open

Chaiprasert T, Armartmuntree N, Techasen A, Sakonsinsiri C, Pinlaor S, Ungarreevittaya P, Khuntikeo N, Namwat N, Thanan R. Roles of Zinc Finger Protein 423 in Proliferation and Invasion of Cholangiocarcinoma through Oxidative Stress. Biomolecules 2019;9:biom9070263. [PMID: 31284679 PMCID: PMC6681239 DOI: 10.3390/biom9070263] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Revised: 06/26/2019] [Accepted: 07/03/2019] [Indexed: 12/21/2022] Open

Zhang HW, Kou K, Qi J, Xie EB, Wang M, Li Y, Lv GY, Wang GY. Mixed adenoneuroendocrine carcinoma of the extrahepatic bile duct: a case report. J Int Med Res 2019;47:3421-3426. [PMID: 31154920 PMCID: PMC6683900 DOI: 10.1177/0300060519850391] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open

Tariq NUA, McNamara MG, Valle JW. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res 2019;11:2623-2642. [PMID: 31015767 PMCID: PMC6446989 DOI: 10.2147/cmar.s157092] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open

Zhang BL, Ji X, Yu LX, Gao Y, Xiao CH, Liu J, Zhao DX, Le Y, Diao GH, Sun JY, Li GH, Lei GL, Yu P, Wang RL, Wu JZ, Yang PH, Yan J, Li JY, Xu JJ, Zhang SG, Tian H. Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing. Oncol Lett 2018;16:6003-6012. [PMID: 30344748 DOI: 10.3892/ol.2018.9371] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Accepted: 07/13/2018] [Indexed: 12/23/2022] Open

Abstract

Liver and biliary cancers are highly lethal cancer types lacking effective treatments. The somatic mutations, particularly those with low mutant allele frequencies, in Chinese patients with liver and biliary cancer have not been profiled, and the frequency of patients benefiting from targeted therapy has not been studied. The present study evaluated the tumor tissues of 45 Chinese patients with hepatocellular carcinoma (HCC) and 12 Chinese patients with biliary tract cancer (BTC) by targeted next generation sequencing, with an average coverage of 639×, to identify alterations in 372 cancer-related genes. A total of 263 variants were identified in 139 genes, with 85.6% of these variants not previously reported in the Catalogue Of Somatic Mutations In Cancer database, and the mutation profile was different from the current datasets, including The Cancer Genome Atlas dataset and the National Cancer Center Japan (NCC_JP) dataset. Patients with hepatitis B virus (HBV) infection harbored more mutations than those without HBV infection, and the mutations in HBV carriers occurred preferentially in genes involved in vascular endothelial growth factor signaling pathways. Mutations in fibroblast growth factor and RAS signaling pathways were enriched in patients with cirrhosis, and alterations in interleukin and transforming growth factor signaling pathways were more frequently identified in individuals with abnormal bilirubin expression. Of all the patients, 7% exhibited variants in the target of sorafenib, and 42% harbored variants in the targets of drugs that have been approved to treat other types of cancer. These findings indicate diverse HCC/BTC variants patterns in different populations, and that the mutation load and patterns are correlated with clinical features. Further clinical studies are now warranted to evaluate the efficacies of other targeted drugs besides sorafenib in the treatment of patients with liver and biliary cancer.

Collapse

Affiliation(s)

Bo-Lun Zhang Department of General Surgery, Clinical Medical College of Weifang Medical University, Weifang, Shandong 261042, P.R. China
Xu Ji Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Ling-Xiang Yu Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Yuan Gao Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Chao-Hui Xiao Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Jia Liu Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
De-Xi Zhao Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Yi Le Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Guang-Hao Diao Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Jia-Yi Sun Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Gao-Hua Li Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Guang-Lin Lei Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Peng Yu Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Rui-Lan Wang Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Jian-Zhong Wu Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Peng-Hui Yang Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Jin Yan Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Jing-Yu Li Institute of Precision Medicine, 3D Medicines, Inc., Shanghai 201114, P.R. China
Jia-Jia Xu Institute of Precision Medicine, 3D Medicines, Inc., Shanghai 201114, P.R. China
Shao-Geng Zhang Department of Hepatobiliary Surgery, 302 Military Hospital of China, Beijing 100039, P.R. China
Hu Tian Department of Hepatobiliary Surgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China

Collapse

Lu Y, Yan B, Guo H, Qiu L, Sun X, Wang X, Shi Q, Bao Y. Effect of midkine on gemcitabine resistance in biliary tract cancer. Int J Mol Med 2018;41:2003-2011. [PMID: 29344648 PMCID: PMC5810218 DOI: 10.3892/ijmm.2018.3399] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Accepted: 01/04/2018] [Indexed: 12/19/2022] Open

Fábrega-Foster K, Ghasabeh MA, Pawlik TM, Kamel IR. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2017;6:67-78. [PMID: 28503554 DOI: 10.21037/hbsn.2016.12.10] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]

Feng F, Cheng Q, Yang L, Zhang D, Ji S, Zhang Q, Lin Y, Li F, Xiong L, Liu C, Jiang X. Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing. Oncotarget 2017;8:5349-5360. [PMID: 28029662 PMCID: PMC5354913 DOI: 10.18632/oncotarget.14146] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Accepted: 11/22/2016] [Indexed: 12/29/2022] Open

Abstract

PURPOSE

Gallbladder sarcomatoid carcinoma is a rare cancer with no clinical standard treatment. With the rapid development of next generation sequencing, it has been able to provide reasonable treatment options for patients based on genetic variations. However, most cancer drugs are not approval for gallbladder sarcomatoid carcinoma indications. The correlation between drug response and a genetic variation needs to be further elucidated.

EXPERIMENTAL DESIGN

Three patient-derived cells-JXQ-3D-001, JXQ-3D-002, and JXQ-3D-003, were derived from biopsy samples of one gallbladder sarcomatoid carcinoma patient with progression and have been characterized. In order to study the relationship between drug sensitivity and gene alteration, genetic mutations of three patient-derived cells were discovered by whole exome sequencing, and drug screening has been performed based on the gene alterations and related signaling pathways that are associated with drug targets.

RESULTS

It has been found that there are differences in biological characteristics such as morphology, cell proliferation, cell migration and colony formation activity among these three patient-derived cells although they are derived from the same patient. Their sensitivities to the chemotherapy drugs-Fluorouracil, Doxorubicin, and Cisplatin are distinct. Moreover, none of common chemotherapy drugs could inhibit the proliferations of all three patient-derived cells. Comprehensive analysis of their whole exome sequencing demonstrated that tumor-associated genes TP53, AKT2, FGFR3, FGF10, SDHA, and PI3KCA were mutated or amplified. Part of these alterations are actionable. By screening a set of compounds that are associated with the genetic alteration, it has been found that GDC-0941 and PF-04691502 for PI3K-AKT-mTOR pathway inhibitors could dramatically decrease the proliferation of three patient-derived cells. Importantly, expression of phosphorylated AKT and phosphorylated S6 were markedly decreased after treatments with PI3K-AKT-mTOR pathway inhibitors GDC-0941 (0.5 μM) and PF-04691502 (0.1 μM) in all three patient-derived cells. These data suggested that inhibition of the PI3K-AKT-mTOR pathway that was activated by PIK3CA amplification in all three patient-derived cells could reduce the cell proliferation.

CONCLUSIONS

A patient-derived cell model combined with whole exome sequencing is a powerful tool to elucidate relationship between drug sensitivities and genetic alternations. In these gallbladder sarcomatoid carcinoma patient-derived cells, it is found that PIK3CA amplification could be used as a biomarker to indicate PI3K-AKT-mTOR pathway activation. Block of the pathway may benefit the gallbladder sarcomatoid carcinoma patient with this alternation in hypothesis. The real efficacy needs to be confirmed in vivo or in a clinical trial.

Collapse

The Importance of Imaging Techniques in the Assessment of Biliary Tract Cancer. CURRENT HEALTH SCIENCES JOURNAL 2017;43:201-208. [PMID: 30595876 PMCID: PMC6284837 DOI: 10.12865/chsj.43.03.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Accepted: 09/01/2017] [Indexed: 11/16/2022]

[Diagnostics and treatment of cholangiocellular carcinoma]. Internist (Berl) 2016;57:1191-1205. [PMID: 27822622 DOI: 10.1007/s00108-016-0128-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]

Takahashi H, Moslim MA, Presser N, O'Rourke C, Wey J, Chalikonda S, Walsh MR, Morris-Stiff G. Absence of a Periampullary Mass on Cross-sectional Imaging Delays Diagnosis and Time to Pancreatoduodenectomy But Does Not Impair Outcome. J Gastrointest Surg 2016;20:1179-87. [PMID: 26984696 DOI: 10.1007/s11605-016-3127-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Accepted: 03/04/2016] [Indexed: 01/31/2023]

Zheng SL, Yip VS, Pedica F, Prachalias A, Quaglia A. Intrahepatic bile duct mixed adenoneuroendocrine carcinoma: a case report and review of the literature. Diagn Pathol 2015;10:204. [PMID: 26589730 PMCID: PMC4654861 DOI: 10.1186/s13000-015-0439-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 11/12/2015] [Indexed: 12/16/2022] Open

Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-181. [PMID: 26623263 PMCID: PMC4663198 DOI: 10.14218/jcth.2015.00012] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Revised: 05/22/2015] [Accepted: 05/26/2015] [Indexed: 02/06/2023] Open

Popp FC, Weigt J, Kalinski T, Betzler C, Arend J, Garlipp B, Benckert C, Bruns CJ. [Papillary tumors - therapeutic concepts]. Chirurg 2015. [PMID: 26223666 DOI: 10.1007/s00104-015-0048-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]